不同治疗方式对早产儿动脉导管未闭的疗效及安全性评价

陈丹; 毛健

doi:10.7499/j.issn.1008-8830.2015.10.003

PDF(1307 KB)

HTML

中国当代儿科杂志 ›› 2015, Vol. 17 ›› Issue (10) : 1032-1038. DOI: 10.7499/j.issn.1008-8830.2015.10.003

论著·临床研究

不同治疗方式对早产儿动脉导管未闭的疗效及安全性评价

陈丹, 毛健

作者信息 +

Evaluation of therapeutic effects and safety of different treatment methods for premature patent ductus arteriosus

CHEN Dan, MAO Jian

Author information +

文章历史 +

摘要

目的探讨早产儿动脉导管未闭(PDA)的临床治疗方式及效果,总结手术治疗PDA 的经验。方法 2013 年1 月至2014 年12 月诊断为PDA 并行手术治疗的早产儿19 例为手术组,同期未行手术治疗的19 例PDA 早产儿为非手术组。分析两组在病史因素、临床因素、病死率及主要并发症等方面的差异,同时从术前准备及手术结果方面分析手术治疗的特点及临床效果。结果非手术组早产儿胎龄及出生体重均大于手术组(P<0.01),且生后1 min 及5 min Apgar 评分均高于手术组(P<0.05);手术组患儿PDA 直径、超声确诊时间及辅助通气时间均大于非手术组,且药物治疗、左心房/主动脉根部(LA/AO)比值>1.3 及导管直径的平方/出生体重(d²/BW)比值>9 mm²/kg 的发生率均高于非手术组(P<0.05);手术组早产儿BPD 发生率高于非手术组(P<0.01);而死亡、脑白质损伤、颅内出血和NEC 发生率在两组间比较差异均无统计学意义(P>0.05)。结论对有临床症状且内科保守治疗或药物治疗无好转的早产儿PDA,外科结扎术是相对安全有效的方法。

Abstract

Objective To explore the clinical treatment methods and their effects in the treatment of premature patent ductus arteriosus (PDA) and to summarize the experience of surgical treatment for PDA. Methods Nineteen premature infants who were diagnosed with PDA and received surgical treatment betwen January 2013 and December 2014 were selected as the surgical group, and 19 premature infants with PDA who did not receive surgical treatment during the same period were selected as the non-surgical group. The differences in medical history, clinical conditions, mortality, and major complications between the two groups were analyzed, and the characteristics of surgical treatment and its clinical effects were analyzed from the aspects of preoperative preparation and surgical results. Results Compared with the surgical group, the gestational age and birth weight in the non-surgical group were significantly greater (P<0.01), and Apgar scores for 1 and 5 minutes after birth were significantly higher in the non-surgical group (P<0.05). The PDA diameter, time to confirmed ultrasonic diagnosis, and duration of auxiliary ventilation in the surgical group were greater than in the non-surgical group, and the incidence of drug therapy, left atrium/aortic root (LA/AO) ratio >1.3, and the square of catheter diameter/birth weight (d²/BW) ratio >9 mm²/kg in the surgical group was significantly higher than in the non-surgical group (P<0.05). Compared with the non-surgical group, the surgical group had a significantly higher incidence of bronchopulmonary dysplasia (P<0.01), and there were no significant differences in the incidence of death, cerebral white matter damage, intracranial hemorrhage, and necrotizing enterocolitis between the two groups (P>0.05). Conclusions For premature infants with clinical symptoms and no improvement after conservative medical treatment or drug therapy, surgical ligation is a relatively safe and effective treatment method for PDA.

导出引用

陈丹, 毛健. 不同治疗方式对早产儿动脉导管未闭的疗效及安全性评价[J]. 中国当代儿科杂志. 2015, 17(10): 1032-1038 https://doi.org/10.7499/j.issn.1008-8830.2015.10.003

CHEN Dan, MAO Jian. Evaluation of therapeutic effects and safety of different treatment methods for premature patent ductus arteriosus[J]. Chinese Journal of Contemporary Pediatrics. 2015, 17(10): 1032-1038 https://doi.org/10.7499/j.issn.1008-8830.2015.10.003

参考文献

[1] Hsiao CC, Wung JT, Tsao LY, et al. Early or late surgical ligation of medical refractory patent ductus arteriosus in premature infants[J]. J Formos Med Assoc, 2009, 108(1):72-77.
[2] Evans N. Preterm patent ductus arteriosus:should we treat it?[J]. J Paediatr Child Health, 2012, 48(9):753-758.
[3] Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus:are current neonatal treatment options better or worse than no treatment at all?[J]. Semin Perinatol, 2012, 36(2):123-129.
[4] Meyer S. PDA in neonates-please doctor act individually![J]. Acta Paediatr, 2012, 101(4):145-146.
[5] Schena F, Ciarmoli E, Mosca F. Patent ductus arteriosus:wait and see?[J]. J Matern Fetal Neonatal Med, 2011, 24(3):2-4.
[6] Mezu-Ndubuisi OJ, Agarwal G, Raghavan A, et al. Patent ductus arteriosus in premature neonates[J]. Drugs, 2012, 72(7):907-916.
[7] Saldeno YP, Favareto V, Mirpuri J. Prolonged persistent patent ductus arteriosus:potential perdurable anomalies in premature infants[J]. J Perinatol, 2012, 32(12):953-958.
[8] Markham M. Patent ductus arteriosus in the premature infant:a clinical dilemma[J]. Newborn Infant Nurs Rev, 2006, 6(3):151-157.
[9] Sarkar S, Dechert R, Schumacher RE, et al. Is refractory hypotension in preterm infants a manifestation of early ductal shunting?[J]. J Perinatol, 2007, 27(6):353-358.
[10] Koch J, Hensley G, Roy L, et al. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less[J]. Pediatrics, 2006, 117(4):1113-1121.
[11] Alexander F, Chiu L, Kroh M, et al. Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus[J]. J Pediatr Surg, 2009, 44(1):112-117.
[12] Jhaveri N, Moon-Grady A, Clyman RI. Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment[J]. J Pediatr, 2010, 157(3):381-387.
[13] Hammerman C, Aramburo MJ. Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus[J]. J Pediatr, 1990, 117(5):771-776.
[14] Abdel-Hady H, Nasef N, Shabaan AE, et al. Patent ductus arteriosus in preterm infants:do we have the right answers?[J]. Biomed Res Int, 2013, 2013:676192.
[15] Davis P, Turner-Gomes S, Cunningham K, et al. Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus[J]. Arch Pediatr Adolesc Med, 1995, 149(10):1136-1141.
[16] Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus:a randomised controlled trial[J]. Eur J Pediatr, 2002, 161(4):202-207.
[17] Wyllie J. Treatment of patent ductus arteriosus[J]. Semin Neonatol, 2003, 8(6):425-432.
[18] De Buyst J, Rakza T, Pennaforte T, et al. Hemodynamic effects of fluid restriction in preterm infants with significant patent ductus arteriosus[J]. J Pediatr, 2012, 161(3):404-408.
[19] Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants[J]. Cochrane Database Syst Rev, 2014, (12):CD000503.
[20] Noori S, Patel D, Friedlich P, et al. Effects of low oxygen saturation limits on the ductus arteriosus in extremely low birth weight infants[J]. J Perinatol, 2009, 29(8):553-557.
[21] Gersony WM, Peckham GJ, Ellison RC, et al. Effects of indomethacin in premature infants with patent ductus arteriosus:results of a national collaborative study[J]. J Pediatr, 1983, 102(6):895-906.
[22] Kushnir A, Pinheiro JM. Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts[J]. BMC Clin Pharmacol, 2011, 11:8.
[23] Richards J, Johnson A, Fox G, et al. A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants[J]. Pediatrics, 2009, 124(2):287-293.
[24] van der Lugt NM, Lopriore E, Bokenkamp R, et al. Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus[J]. Eur J Pediatr, 2012, 171(11):1673-1677.
[25] Keady S, Grosso A. Ibuprofen in the management of neonatal Patent Ductus Arteriosus[J]. Intensive Crit Care Nurs, 2005, 21(1):56-58.
[26] Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants[J]. Cochrane Database Syst Rev, 2010, (4):CD003481.
[27] Jones LJ, Craven PD, Attia J, et al. Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants[J]. Arch Dis Child Fetal Neonatal Ed, 2011, 96(1):45-52.
[28] Oncel MY, Yurttutan S, Uras N, et al. An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants[J]. Arch Dis Child Fetal Neonatal Ed, 2013, 98(1):94.
[29] Oncel MY, Yurttutan S, Degirmencioglu H, et al. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants[J]. Neonatology, 2013, 103(3):166-169.
[30] Hansen TW. Patency of the ductus arteriosus in the newborn-Now you want it, now you don't[J]. Pediatr Crit Care Med, 2007, 8(3):302-303.
[31] Malviya M, Ohlsson A, Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants[J]. Cochrane Database Syst Rev, 2008, (1):CD003951.
[32] Schena F, Ciarmoli E, Mosca E. Patent ductus arteriosus:wait and see?[J]. J Matern Fetal Neonatal Med, 2011, 24(3):2-4.
[33] Vida VL, Lago P, Salvatori S, et al. Is there an optimal timing for surgical ligation of patent ductus arteriosus in preterm infants?[J]. Ann Thorac Surg, 2009, 87(5):1509-1515.
[34] Tschuppert S, Doell C, Arlettaz-Mieth R, et al. The effect of ductal diameter on surgical and medical closure of patent ductus arteriosus in preterm neonates:size matters[J]. J Thorac Cardiovasc Surg, 2008, 135(1):78-82.
[35] 朱燕林, 郭立琳, 徐瑞燚, 等. 极低体重早产儿动脉导管未闭的治疗[J]. 临床心血管病杂志, 2011, 27(9):700-702.
[36] Boo NY, Cheah IG. Risk factors associated with necrotising enterocolitis in very low birth weight infants in Malaysian neonatal intensive care units[J]. Singapore Med J, 2012, 53(12):826-831.
[37] Baruteau AE, Hascoet S, Baruteau J, et al. Transcatheter closure of patent ductus arteriosus:past, present and future[J]. Arch Cardiovasc Dis, 2014, 107(2):122-132.
[38] Lee JH, Shin JH, Park KH, et al. Can early B-type natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants?[J]. Neonatology, 2013, 103(2):118-122.
[39] Hsu JH, Yang SN, Chen HL, et al. B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus[J]. J Pediatr, 2010, 157(1):79-84.
[40] Letzner J, Berger F, Schwabe S, et al. Plasma C-terminal proendothelin-1 and the natriuretic pro-peptides NT-proBNP and MR-proANP in very preterm infants with patent ductus arteriosus[J]. Neonatology, 2012, 101(2):116-124.